Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.78 |
| ▸ | NPC1 | O15118 | 12/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.78 |
| ▸ | PKM | P14618 | 4/20 | 0.78 |
| ▸ | GAA | P10253 | 4/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SCD | O00767 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658434 | 0.88 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL9911667 | 0.85 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL31430447 | 0.84 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL21066436 | 0.84 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL19899736 | 0.84 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL29236673 | 0.84 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL1163272 | 0.83 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL20195816 | 0.83 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL2373205 | 0.83 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2PKMGAA | |
| SCHEMBL28637996 | 0.83 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111933818-A | Organic light-emitting device | 长春海谱润斯科技有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | RAB9A 3425/4885NPC1 1248/4885SMN1; SMN2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.